The first anti-FRα MAB, farletuzumab (MORab003; Morphotek, Inc., Exton, PA, USA), demonstrated anticancer activities possibly by activating the complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and persistent autophagy of tumor cells, resulting in decreased cell proliferation and the inhibition of the Lyn kinase signaling pathway [5,89]. The gene discussed is FOLR1; the disease is neoplasm.